<?xml version="1.0" encoding="UTF-8"?>
<p>Inhibitors that specifically target integration have also been approved for the treatment of HIV infection. Since integrase is a necessary enzyme for the replication step involving the integration of host cell DNA to the viral genome, it has become a validated target for developing anti-HIV agents (
 <xref rid="B76" ref-type="bibr">Hazuda et al., 2000</xref>; 
 <xref rid="B187" ref-type="bibr">Pommier et al., 2005</xref>; 
 <xref rid="B5" ref-type="bibr">Antonelli and Turriziani, 2012</xref>). New integrase inhibitors targeting Gag, as an antiviral target, indicated auspicious effects both in preclinical and clinical trials (
 <xref rid="B159" ref-type="bibr">Min et al., 1999b</xref>; 
 <xref rid="B187" ref-type="bibr">Pommier et al., 2005</xref>; 
 <xref rid="B66" ref-type="bibr">Grinsztejn et al., 2007</xref>).
</p>
